Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a young adult with primary follicular mucinosis, successfully treated with topical tacrolimus, resulting in resolution without sequelae.

This study observed that early treatment with ritlecitinib in patients with alopecia areata, especially when severity is low, led to more favorable responses, and continued improvement was seen up to 24 months, offering guidance on treatment timing and duration.

This study found that platelet-rich plasma therapy reduced inflammation and improved bladder function in a rat model of ketamine-induced ulcerative cystitis.

This study reported that in a mouse tail wound model, the synthetic dual inhibitor corin accelerated wound closure by enhancing re-epithelialization, and further in vitro experiments demonstrated increased expression of genes promoting keratinocyte migration, suggesting its potential as a treatment for chronic wounds.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

This study identified the NAC transcription factor RD26 as a critical regulator of drought-induced root hair growth restriction in Arabidopsis thaliana, with a similar mechanism observed in tomatoes, indicating evolutionary conservation.

This review discusses the potential role of JAK inhibitors, like ruxolitinib, as emerging therapeutic agents in dermatology, but reports no new clinical results.

The researchers reported that iPSCs derived from Sendai virus reprogrammed blood cells can mature into functional keratinocytes for up to 60 days, potentially offering new approaches for DEB treatment.

In this study, researchers developed a versatile sprayable hydrogel that promotes wound healing in mice by facilitating rapid gelation, reducing inflammation, and accelerating tissue regeneration, with potential applications in chronic wound treatment and beyond.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

This study developed a technology for a combined gel named "Biosedum Plus" intended for treating and preventing radiation skin damage, detailing its formulation and critical processing parameters.

This article discusses the crucial role of root hairs in water and nutrient uptake from soil and reports no new findings.

In this study, patients with treatment-refractory alopecia areata who received oral ritlecitinib 50 mg daily experienced significant hair regrowth, with 52.6% achieving complete scalp regrowth and improved Severity of Alopecia Tool scores, indicating its potential effectiveness in real-world settings.

This article discusses the importance of differential diagnosis and adequate treatment for tinea capitis, a common scalp infection in children, and reports no new results.

In this case study, an 11-year-old girl with severe alopecia areata experienced complete hair regrowth and unexpected white-to-black hair repigmentation after switching from baricitinib to ritlecitinib, suggesting that prolonged Janus kinase inhibition may aid both hair and pigment restoration in severe pediatric cases.

This study found that the oral JAK inhibitors ritlecitinib and brepocitinib were effective in maintaining hair regrowth in alopecia areata with continuous use, though efficacy decreased after withdrawal.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

This study describes characteristics and outcomes for adults initiating ritlecitinib for severe alopecia areata, highlighting increased hair regrowth and physician satisfaction with longer treatment durations, despite ongoing psychosocial impacts like embarrassment and anxiety among patients.

ChatGPT-4 can help with allergic contact dermatitis but shouldn't replace expert doctors.

This study found that the oral IRAK4-inhibitors BAY 1834845 and BAY 1830839 reduced skin inflammation and systemic inflammatory responses in healthy volunteers, showing similar pharmacodynamic effects to prednisolone when challenged with topical imiquimod and intravenous LPS.

This study reported that reconstructed skin models can be useful for studying the effects of non-water-soluble topical products on xenobiotic metabolism, particularly in enzyme activities like EROD and GST.

This systematic literature review identified kale leaf hair tonic (Ipomoea aquatica Forsk.) at 5% concentration as an effective herbal cosmeceutical preparation for enhancing hair growth, showing an average increase in hair length over 21 days, while meeting established pharmaceutical standards.

This study developed BroadAMP-GPT, a computational-experimental framework, to discover new antimicrobial peptides, identifying candidates effective against multidrug-resistant pathogens. Notably, AMP_S13 showed strong stability, low toxicity, and efficacy in infection models, highlighting the platform's potential in combating antimicrobial resistance.

This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.